CPRX Quote, Financials, Valuation and Earnings

Rigel Pharmaceuticals, Inc. has a net margin of 35.57% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 40.17%. Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.57, signalling upside risk potential of 41.45%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.60 which suggests that it could grow by 51.1%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Catalyst Pharmaceuticals, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Catalyst Pharmaceuticals, Inc..

Catalyst Pharmaceuticals, Inc. has a beta of 0.735, which suggesting that the stock is 26.455% less volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.111, suggesting its more volatile than the S&P 500 by 11.137%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $148.4M, which are larger than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Catalyst Pharmaceuticals, Inc.'s net income of $52.8M is higher than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 14.26x while Rigel Pharmaceuticals, Inc.'s PE ratio is 5.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 5.37x versus 2.22x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals, Inc. has a net margin of 35.57% compared to Catalyst Pharmaceuticals, Inc.'s net margin of -23.49%. Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48% beat Supernus Pharmaceuticals, Inc.'s return on equity of -1.84%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.57, signalling upside risk potential of 41.45%. On the other hand Supernus Pharmaceuticals, Inc. has an analysts' consensus of $61.33 which suggests that it could grow by 18.75%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Supernus Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Supernus Pharmaceuticals, Inc..

Catalyst Pharmaceuticals, Inc. has a beta of 0.735, which suggesting that the stock is 26.455% less volatile than S&P 500. In comparison Supernus Pharmaceuticals, Inc. has a beta of 0.706, suggesting its less volatile than the S&P 500 by 29.381%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Supernus Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $148.4M, which are smaller than Supernus Pharmaceuticals, Inc. quarterly revenues of $192.1M. Catalyst Pharmaceuticals, Inc.'s net income of $52.8M is higher than Supernus Pharmaceuticals, Inc.'s net income of -$45.1M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 14.26x while Supernus Pharmaceuticals, Inc.'s PE ratio is 41.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 5.37x versus 4.27x for Supernus Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics Corp. has a net margin of 35.57% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 42.36%. Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48% beat United Therapeutics Corp.'s return on equity of 19.2%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.57, signalling upside risk potential of 41.45%. On the other hand United Therapeutics Corp. has an analysts' consensus of $531.25 which suggests that it could grow by 9.46%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than United Therapeutics Corp..

Catalyst Pharmaceuticals, Inc. has a beta of 0.735, which suggesting that the stock is 26.455% less volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.572%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $148.4M, which are smaller than United Therapeutics Corp. quarterly revenues of $799.5M. Catalyst Pharmaceuticals, Inc.'s net income of $52.8M is lower than United Therapeutics Corp.'s net income of $338.7M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 14.26x while United Therapeutics Corp.'s PE ratio is 18.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 5.37x versus 7.48x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis, Inc. has a net margin of 35.57% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 30.04%. Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48% beat Zoetis, Inc.'s return on equity of 52.95%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.57, signalling upside risk potential of 41.45%. On the other hand Zoetis, Inc. has an analysts' consensus of $152.81 which suggests that it could grow by 19.93%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Zoetis, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Zoetis, Inc..

Catalyst Pharmaceuticals, Inc. has a beta of 0.735, which suggesting that the stock is 26.455% less volatile than S&P 500. In comparison Zoetis, Inc. has a beta of 0.962, suggesting its less volatile than the S&P 500 by 3.849%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis, Inc. offers a yield of 1.59% to investors and pays a quarterly dividend of $0.53 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Zoetis, Inc. pays out 32.86% of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $148.4M, which are smaller than Zoetis, Inc. quarterly revenues of $2.4B. Catalyst Pharmaceuticals, Inc.'s net income of $52.8M is lower than Zoetis, Inc.'s net income of $721M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 14.26x while Zoetis, Inc.'s PE ratio is 21.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 5.37x versus 6.06x for Zoetis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.